OMEROS CORP Receivables, Net, Current
OMEROS CORP (OMER) had Receivables, Net, Current of $21.30 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets › Assets, Current › Receivables, Net, Current
us-gaap:ReceivablesNetCurrent · last filed 2026-08-12
- 2026-06-30: Receivables, Net, Current $21.30M.
- 2026-03-31: Receivables, Net, Current $12.03M.
- 2025-12-31: Receivables, Net, Current $10.92M.
- 2025-09-30: Receivables, Net, Current $6.91M.
| Period end | Receivables, Net, Current |
|---|---|
| 2026-06-30 | $21.30M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $12.03M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $10.92M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $6.91M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $6.28M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $7.08M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $7.74M 10-K · filed 2026-03-31 |
| 2024-09-30 | $6.39M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $8.08M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $7.64M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $8.10M 10-K · filed 2025-03-31 |
| 2023-09-30 | $6.88M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $11.19M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $10.03M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $213.22M 10-K · filed 2024-04-01 |
| 2022-09-30 | $13.85M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $14.48M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $16.25M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $38.16M 10-K · filed 2023-03-13 |
| 2021-09-30 | $33.90M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $31.84M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $24.83M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $3.84M 10-K · filed 2022-03-01 |
| 2020-09-30 | $37.38M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $15.78M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $24.12M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $35.19M 10-K · filed 2021-03-01 |
| 2019-09-30 | $29.93M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $28.52M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $24.72M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $22.82M 10-K · filed 2020-03-02 |
| 2018-09-30 | $2.30M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $1.53M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $182.00K 10-Q · filed 2018-05-10 |
| 2017-12-31 | $17.14M 10-K · filed 2019-03-01 |
| 2017-09-30 | $24.57M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $19.07M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $13.48M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $12.04M 10-K · filed 2018-03-01 |
| 2016-09-30 | $10.46M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $8.81M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $6.65M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $6.52M 10-K · filed 2017-03-16 |
| 2015-09-30 | $2.51M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $3.07M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $538.00K 10-Q · filed 2015-05-11 |
| 2014-12-31 | $392.00K 10-K · filed 2016-03-15 |
| 2014-09-30 | $381.00K 10-Q · filed 2014-11-10 |
| 2014-06-30 | $252.00K 10-Q · filed 2014-08-11 |
| 2014-03-31 | $488.00K 10-Q · filed 2014-05-12 |
| 2013-12-31 | $379.00K 10-K · filed 2015-03-16 |
| 2013-09-30 | $881.00K 10-Q · filed 2013-11-07 |
| 2013-06-30 | $715.00K 10-Q · filed 2013-08-09 |
| 2013-03-31 | $2.00M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $1.93M 10-K · filed 2014-03-13 |
| 2012-09-30 | $467.00K 10-Q · filed 2012-11-09 |
| 2012-06-30 | $767.00K 10-Q · filed 2012-08-07 |
| 2012-03-31 | $1.64M 10-Q · filed 2012-05-10 |
| 2011-12-31 | $876.00K 10-K · filed 2013-03-18 |
| 2011-09-30 | $776.00K 10-Q · filed 2011-11-08 |
| 2011-06-30 | $2.46M 10-Q · filed 2011-08-09 |
| 2010-12-31 | $1.48M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |